We are live on ! Find out more

PROF

Profound Medical

PROF

Market cap $213M

5.82 USD

+0.01

0.17%

At close Updated Sep 15, 12:10 PM EDT

1 day

0.17%

5 days

-14.54%

1 month

-11.15%

3 months

-13.26%

6 months

1.93%

Year to date

-24.02%

1 year

42.3%

5 years

-57.86%

10 years

-41.09%

About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Employees: 162

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.4%

Neutral 76.9%

Negative 7.7%

Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.

Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately.

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'

Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day

Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'

Profound Medical Announces Management Change

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company's Chief Financial Officer.

Profound Medical Announces Management Change

Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey

A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support

Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey

Profound Medical Q2 Earnings Call Highlights

Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June.

Profound Medical Q2 Earnings Call Highlights

Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call Transcript

Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call Transcript

Profound Medical Corp. (PRN:CA) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Profound Medical (PROF) Q2 Earnings Surpass Estimates

Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.

Profound Medical (PROF) Q2 Earnings Surpass Estimates

Profound Medical Reports Second Quarter 2026 Financial Results

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum continues – – Company reiterates full-year 2026 revenue guidance – – Announces first employer owned health plans to list the TULSA Procedure™ as a covered service – TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today announced financial results for the second quarter ended June 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

Profound Medical Reports Second Quarter 2026 Financial Results

Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial

– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – – Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –

Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial

See News Rankings

Price charts implemented using Lightweight Charts™